Cangene announces fiscal 2007 financial results

    Listed TSX, Symbol: CNJ

    TORONTO and WINNIPEG, Oct. 18 /CNW/ - Cangene Corporation today reports
financial results for the fiscal year ended July 31, 2007.
    Revenues for the year were $92.4 million, compared to $109.3 million last
year. Stronger year-over-year WinRho(R) SDF sales in the U.S. and the
commencement of HepaGam B(TM) sales partially offset reduced revenues from VIG
- last year Cangene delivered a $16-million order of VIG to the U.K.
government. There was no equivalent VIG sale in the current year. Higher
royalty revenues also helped offset the resulting decrease in total revenues.
R&D-services revenues in the current year also declined as activity on U.S.
government research contracts awarded in 2003 were completed and R&D
activities related to Accretropin(TM) and Leucotropin(R), two follow-on
biopharmaceutical products being developed jointly with the Apotex Group, had
diminished following their submission for regulatory review. The Company is
not yet recognizing contract-services revenues related to government
stockpiling contracts signed during fiscal 2006; costs associated with these
contracts to-date total $38.0 million and have been charged to inventory,
prepaid expenses and other assets.
    "We successfully executed on our plans during 2007 to achieve the
critical Usable Product milestone for the two significant U.S. stockpiling
contracts," said Dr. John Langstaff, president and CEO of Cangene. "And,
although these milestones were reached after the year-end meaning that
US$18-22 million of revenue, which could have been recorded in fiscal 2007 if
the milestones had been reached just a few weeks earlier, was not included in
the fiscal year, we still posted solid financial results in 2007. We
anticipate these contract revenues will favourably impact our results in the
first quarter of fiscal 2008," he said.
    Net income for the year was $10.1 million or $0.15 per share, compared
with $13.1 million or $0.20 per share a year earlier. Despite reduced
revenues, gross profit in the current year increased to $50.0 million or 54%
of revenue, compared with $48.4 million or 44% of revenue during the same
period last year. The increase in gross profit and improved margins are due to
increased sales of the higher-margin liquid WinRho(R) SDF in the U.S. coupled
with reduced R&D-services revenues and VIG sales, which have relatively lower
gross margins. Higher operating costs, which include increased expenditures on
independent R&D projects, a higher amortization expense due to the new
fractionation facility now being operational and the increase in foreign
exchange losses of $2.2 million, contributed to the reduced level of earnings
in fiscal 2007.
    Working capital balances related to operations increased by
$21.6 million, due mainly to higher inventories, prepaid expenses and other
assets resulting from the start-up of the anthrax immune globulin and botulism
antitoxin stockpiling contracts. Long-term debt has been reduced by
$29.8 million from the balance at the 2006 fiscal year-end as the Company has
repaid $29.0 million of the non-revolving term loan used to finance the
fractionation-plant expansion. The Company immediately used $24.0 million of
the proceeds from the common share offering that closed in December 2006 for
that purpose, while additional repayments of $5.0 million were made during the
remainder of 2007.
    Certain comparative figures in the financial statements have been
reclassified to conform to the current year's presentation.

    Conference Call

    Cangene will host a conference call to discuss these financial results on
October 19, 2007 at 11:00 a.m. E.S.T. To access the conference call by
telephone, dial 416-644-3416 or 1-800-732-9303. Please connect approximately
15 minutes prior to the beginning of the call to ensure participation. The
conference call will be archived for replay until Friday, October 26, 2007 at
midnight. To access the archived conference call, dial 416-640-1917 or
1-877-289-8525 and enter the reservation number 21250750 followed by the
number sign.
    A live audio webcast of the conference call will be available at and Please connect at least 15 minutes prior
to the conference call to ensure adequate time for any software download that
may be required to join the webcast. The webcast will be archived at the above
web sites for 90 days.

    Glossary of Products

    Accretropin(TM):  Cangene's Human Growth Hormone

    HepaGam B(TM):    Cangene's Hepatitis B Immune Globulin (Human) Injection

    Leucotropin(R):   Cangene's version of a protein called granulocyte-
                      macrophage colony-stimulating factor ("GM-CSF") that
                      stimulates the production of certain white blood cells

    VIG:              Vaccinia Immune Globulin Intravenous (Human), used for
                      treating certain complications that may arise due to
                      smallpox vaccination

    WinRho(R) SDF     Rh(o) (D) Immune Globulin (Human), which reacts with
                      certain types of red blood cells and is used for
                      treating hemolytic disease of the newborn and immune
                      thrombocytopenic purpura ("ITP")


    in thousands of                                     As at          As at
    Canadian dollars                            July 31, 2007  July 31, 2006

    Cash                                            $       -      $   7,691
    Accounts receivable                                20,475         26,956
    Income and other taxes recoverable                 16,144          3,291
    Inventories                                        60,753         27,170
    Prepaid expenses and deposits                       3,105          2,640
    Total current assets                              100,477         67,748
    Property, plant and equipment, net                103,571        105,392
    Future income taxes                                 9,373          9,941
    Goodwill                                           40,514         40,514
    Other assets                                        2,815          1,559
                                                    $ 256,750      $ 225,154

    Bank indebtedness                               $   2,136      $       -
    Accounts payable and accrued liabilities           23,140         16,009
    Income and other taxes payable                        450            -
    Current portion of deferred income                  3,623          4,532
    Current portion of long-term debt                   1,636          5,674
    Total current liabilities                          30,985         26,215
    Long-term debt                                      1,112         26,854
    Incentive plan liability                              226            760
    Deferred income                                     2,931          3,770
    Future income taxes                                10,831          1,618
    Total liabilities                                  46,085         59,217
    Shareholders' equity
    Share capital                                      66,894         32,250
    Contributed surplus                                 3,239          3,239
    Cumulative translation adjustment                  (4,467)        (4,467)
    Retained earnings                                 144,999        134,915
    Total shareholders' equity                        210,665        165,937
                                                    $ 256,750      $ 225,154


    in thousands of Canadian dollars               Year ended     Year ended
    except share-related data                   July 31, 2007  July 31, 2006

    Product sales and services                      $  58,844      $  68,899
    R&D services                                       25,281         33,925
    Royalties                                           8,271          6,512
                                                       92,396        109,336

    Cost of sales
    Product sales and services                         27,021         40,637
    R&D services                                       15,370         20,278
                                                       42,391         60,915

    Gross profit                                       50,005         48,421

    Independent R&D                                     6,709          4,674
    Selling, general and administrative                12,957         12,763
    Amortization                                       10,314          9,188
      Short-term                                         (471)           433
      Long-term                                           259            175
    Gain on sale of building                                -           (739)
    Foreign exchange loss (gain)                        1,484           (720)
                                                       31,252         25,774
    Income before income taxes                         18,753         22,647
    Income tax expense
      Current                                           1,910          9,338
      Future                                            6,759            166
                                                        8,669          9,504
    Net income for the year                            10,084         13,143

    Retained earnings, beginning of year              134,915        121,772
    Retained earnings, end of year                  $ 144,999      $ 134,915

    Earnings per share
      Basic and diluted                             $    0.15      $    0.20


    in thousands of                                Year ended     Year ended
    Canadian dollars                            July 31, 2007  July 31, 2006

    Net income for the year                         $  10,084      $  13,143
    Add (deduct) items not involving cash
      Amortization                                     10,314          9,188
      Deferred income                                  (1,748)          (538)
      Net investment tax credits                       (9,122)          (532)
      Incentive plan liability                           (534)           760
      Future income tax expense                         6,759            166
      Gain on disposal of building                          -           (739)
      Unrealized foreign exchange loss on
       future income tax asset                            568            929
                                                       16,321         22,377

    Net change in non-cash working capital
     balances related to operations                   (21,558)         1,016
    Cash provided by (used in) operating activities    (5,237)        23,393

    Purchase of property, plant and equipment          (9,454)       (29,922)
    Proceeds on disposal of building                        -          1,867
    Cash used in investing activities                  (9,454)       (28,055)

    Increase (decrease) in bank indebtedness, net       2,136        (12,172)
    Issuance of long-term debt                              -         24,000
    Repayment of long-term debt                       (29,780)        (2,579)
    Issuance of common shares, net of share
     issuance costs                                    33,501              -
    Proceeds on exercise of stock options               1,143          3,104
    Cash provided by financing activities               7,000         12,353

    Net increase (decrease) in cash during the year    (7,691)         7,691
    Cash, beginning of year                             7,691              -
    Cash, end of year                               $       -      $   7,691

    Interest paid                                   $     563      $   1,657
    Income taxes received                           $    (160)     $  (2,938)

    About Cangene Corporation

    Cangene is one of Canada's largest and earliest biopharmaceutical
companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba.
It uses patented manufacturing processes to produce plasma-derived and
recombinant therapeutic proteins. Cangene has three FDA and Health
Canada-approved products and a fourth that has been approved in Canada only.
One of its recombinant protein products has received an approvable letter from
the FDA and another has been submitted for regulatory review in Canada. In
addition, the Company has several more products in development at various
stages. Three of Cangene's products have been accepted into the U.S. Strategic
National Stockpile-botulism antitoxin, anthrax immune globulin and vaccinia
immune globulin, a product used to counteract certain complications arising
from smallpox vaccination.
    Capitalizing on its drug manufacturing expertise, Cangene also operates a
significant contract research and manufacturing business using its Winnipeg
facilities and the resources of Baltimore, Maryland-based Chesapeake
Biological Laboratories, Inc. (a wholly owned subsidiary). An expansion in
2006 at the Winnipeg location increased the Company's capacity to fractionate
plasma to accommodate the growing manufacturing requirements. Cangene's
website,, includes product and investor information, including
past news releases. Chesapeake's website is

    Forward-looking information

    The reader should be aware that Cangene's businesses are subject to risks
and uncertainties that cannot be predicted or quantified; consequently, actual
results may differ materially from past results and those expressed or implied
by any forward-looking statements. Factors that could cause or contribute to
such risks or uncertainties include, but are not limited to: the regulatory
environment including the difficulty of predicting regulatory outcomes;
changes in the value of the Canadian dollar; the Company's reliance on a small
number of customers including government organizations; the demand for new
products and the impact of competitive products, service and pricing;
availability and cost of raw materials, especially the cost, availability and
antibody concentration in plasma; fluctuations in operating results;
government policies or actions; progress and cost of clinical trials; reliance
on key strategic relationships; costs and possible development delays
resulting from use of legal, regulatory or legislative strategies by the
Company's competitors; uncertainty related to intellectual property protection
and potential cost associated with its defence; the Company's exposure to
lawsuits, and other matters beyond control of management.
    Risks and uncertainties are discussed more extensively in the MD&A
section of the Company's most recent annual report and annual information
form, which are available on the Company's website or on SEDAR at Scientific information that relates to unapproved products or
unapproved uses of products is preliminary and investigative. No conclusions
can or should be drawn regarding the safety or efficacy of such products. Only
regulatory authorities can determine whether products are safe and effective
for the uses being investigated. Healthcare professionals are directed to
refer to approved labelling for products and not rely on information presented
in news releases. Drug names and prescribing information may differ in various
    The cautionary statements referred to above should be considered in
connection with all written or oral statements, especially forward-looking
statements, that are made by the Company or by persons acting on its behalf
and in conjunction with its periodic filings with Securities Commissions,
including those contained in the Company's news releases and most recently
filed annual information form. Forward-looking statements can be identified by
the use of words such as "expects", "plans", "will", "believes", "estimates",
"intends", "may", "bodes" and other words of similar meaning (including
negative and grammatical variations). Should known or unknown risks or
uncertainties materialize, or should management's assumptions prove
inaccurate, actual results could vary materially from those anticipated. The
Company undertakes no obligation to publicly make or update any
forward-looking statements, except as required by applicable law.

    %SEDAR: 00002351E

For further information:

For further information: Michael Graham at (204) 275-4040 or by email at

Organization Profile

Cangene Corporation

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890